Olin Biotech (688319): R&D continues to be invested in phase III clinical promotion of Staphylococcus aureus vaccine
Sales of tetanus vaccine products are steady, and profits are under pressure in the short term. In 2023, the company achieved revenue of 496 million yuan (-9.4% YoY), net profit attributable to mother of 17.56 million yuan (YoY -33.9%), net profit not attributable to mother3
Olin Biotech (688319): Short-term performance is under pressure and we look forward to the progress of the Staphylococcus aureus vaccine
Incident: The company released its 2023 annual report, achieving operating income of 500 million yuan, a year-on-year decrease of 9.4%; realized net profit attributable to shareholders of the parent company of 0.18 million yuan, a year-on-year decrease of 33.9%; realized net profit of 0.3 billion yuan after deduction
Olin Biotech (688319.SH) announced its 2023 annual results, with net profit of 17.56 million yuan, a year-on-year decrease of 33.94%
Olin Biotech (688319.SH) disclosed its 2023 annual report, and the company achieved revenue of 4 in 2023...
Chengdu Olymvax Biopharmaceuticals Inc.'s (SHSE:688319) 30% Share Price Plunge Could Signal Some Risk
To the annoyance of some shareholders, Chengdu Olymvax Biopharmaceuticals Inc. (SHSE:688319) shares are down a considerable 30% in the last month, which continues a horrid run for the company. The
Olin Biotech (688319.SH): The company's products have been exported in small quantities to Pakistan
Gelonghui, April 10 | Olin Biotech (688319.SH) said on the investor interactive platform that the company's products have been exported in small quantities to Pakistan. The human vaccine development cycle is long and the investment is high. In order to maintain continuous competitiveness, the company will steadily advance progress in the research pipeline according to the plan. The country attaches great importance to the human vaccine industry. In recent years, it has introduced a series of policies to support the development of the vaccine industry.
Olin Biotech (688319.SH): Not involved in artificial intelligence-related technology
Gelonghui, March 19 | Olin Biotech (688319.SH) said on the investor interactive platform that the company focuses on the R&D, production and sales of human vaccines. The pilot platform mainly focuses on the development and utilization of vaccines, and does not yet involve artificial intelligence-related technology.
Declining Stock and Decent Financials: Is The Market Wrong About Chengdu Olymvax Biopharmaceuticals Inc. (SHSE:688319)?
Chengdu Olymvax Biopharmaceuticals (SHSE:688319) has had a rough three months with its share price down 45%. But if you pay close attention, you might find that its key financial indicators look qui
Olin Biotech (688319.SH) performance report: 2023 net profit of 174.14,400 yuan, a year-on-year decrease of 34.49%
Gelonghui, Feb. 27丨Olin Biotech (688319.SH) announced its 2023 annual results report. During the reporting period, the company achieved operating income of 496.1187 million yuan, a year-on-year decrease of 9.38%; realized net profit attributable to owners of the parent company was 17.4,104 million yuan, a year-on-year decrease of 34.49%; and realized net profit attributable to owners of the parent company after deducting non-recurring gains and losses of 3.205,500 yuan, an increase of 344.77% year on year.
Express News | Olin Biotech: Withdrawal of AC-HiB Combined Vaccine Drug Registration Application
Chengdu Olymvax Biopharmaceuticals Inc. (SHSE:688319) Shares May Have Slumped 31% But Getting In Cheap Is Still Unlikely
Unfortunately for some shareholders, the Chengdu Olymvax Biopharmaceuticals Inc. (SHSE:688319) share price has dived 31% in the last thirty days, prolonging recent pain. The drop over the last 30 d
Olin Biotech's major combination vaccine may not be approved, and the performance continues to be under pressure
① Olin Biotech initially confirmed that the marketing application for its AC-Hib combination vaccine was not approved. Previously, it was regarded as a “new performance growth point.” ② Olin Biotech is facing declining performance and declining product gross margin year by year.
Is Chengdu Olymvax Biopharmaceuticals (SHSE:688319) Weighed On By Its Debt Load?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor
Chengdu Olymvax Biopharmaceuticals Inc.'s (SHSE:688319) 28% Share Price Plunge Could Signal Some Risk
Chengdu Olymvax Biopharmaceuticals Inc. (SHSE:688319) shares have had a horrible month, losing 28% after a relatively good period beforehand. The last month has meant the stock is now only up 7.2%
Olymvax Biopharmaceuticals Grants Keyuan Xinhai Marketing Rights for Meningococcal Vaccines
Chengdu Olymvax Biopharmaceuticals (SHA:688319) granted Keyuan Xinhai (Beijing) Medical Supplies Trading the right to market the Chinese biopharmaceutical company's Group A and Group C meningococcal p
Olin Biotech (688319.SH) and Keyuan Trading signed a marketing service agreement on AC conjugated vaccine
Olin Biotech (688319.SH) issued an announcement. The company and Keyuan Xinhai (Beijing) Medical Products Trading Co., Ltd...
Olin Biotech: Signed an exclusive marketing service agreement for group A group C meningococcal polysaccharide conjugate vaccine
Glonghui, December 8 | Olin Biotech announced that it has signed an exclusive marketing service agreement for group A group C meningococcal polysaccharide conjugate vaccine, and entrusts Keyuan Trading to carry out nationwide marketing services for the company's AC-conjugated vaccine from 2024 to 2026. The agreement stipulates a total promotion task volume of 4 million doses.
Olin Biotech (688319.SH): No inactivated hepatitis B and polio vaccines
Gelonghui, December 1|Olin Biotech (688319.SH) said on the investor interactive platform that the products currently sold by our company are adsorbed tetanus vaccine, haemophilus influenzae type b conjugate vaccine, group A group C meningococcal polysaccharide conjugate vaccine, and no inactivated hepatitis B or polio vaccines.
Olymvax Biopharmaceuticals to Push Through Phase III Trial Into Recombinant Staphylococcus Aureus Vaccine
Chengdu Olymvax Biopharmaceuticals (SHA:688319) will continue clinical trials into its recombinant Staphylococcus aureus vaccine after receiving the recommendation of an independent data safety monito
Olin Biotech: Staphylococcus aureus vaccine is expected to be revealed in the second half of next year
Glonghui, November 20 | Olin Biotech staff told Blue Whale, who called as investors, that the phase III clinical trial of the recombinant Staphylococcus aureus vaccine (Escherichia coli) has not yet been revealed. Due to the large number of people enrolled in the trial, the total number of cases is expected to reach 6,000. The entire clinical trial is expected to take two years to complete, and is expected to be revealed in the second half of next year. The exact timing will depend on the enrollment situation. The reason for the decline in stock prices is currently unclear; it is possible that the market has different expectations about the timing of the revelation.
Individual Investors Invested in Chengdu Olymvax Biopharmaceuticals Inc. (SHSE:688319) up 7.4% Last Week, Insiders Too Were Rewarded
Key Insights Significant control over Chengdu Olymvax Biopharmaceuticals by individual investors implies that the general public has more power to influence management and governance-related decisions
No Data